Contact
Header_1077x260px_About_Profil.jpg

Artificial pancreas in type 2 diabetes

Close the loop in diabetes care

Artificial pancreas systems are medical products that use algorithms informed by continuous glucose monitoring (CGM) data of a given patient, thereby regulating the rates of a continuous subcutaneous insulin infusion through an insulin pump. In this way, artificial pancreas systems are taking over control of the patient’s blood glucose levels.

Read More

Topics: Diabetes Technology, Treating Diabetes, The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Feb 19, 2019 5:21:00 PM
prof-dr-freimut-schliess

Digital Diabetes: better trials, better drugs, better care

Background

Diabetes is a multidimensional challenge for global societies. Despite the availability of drugs and technology many patients don’t reach their treatment goals.  According to the UK National Diabetes Audit data 2016-2017 only 30% of people with type 1 diabetes and 67% of people with type 2 diabetes achieved a HbA1c target of 58 mmol/l (7.5%). When considering also blood pressure and cholesterol targets, these figures dropped to 19% and 41% respectively.

The good news is that diabetes leaves a huge room for Innovation. Risk factors are modifyable, type 2 diabetes is potentially reversible and the role of the patient’s self-management is of outstanding importance. Diabetes could serve as a paradigm for cracking down treatment inertia and narrowing the gap between the efficacy of investigational medicinal products seen in well controlled clinical trials and the lower than expected effectiveness of drugs observed in real-world chronic care (E2E gap) [1].

Read More

Topics: Diabetes Technology, Treating Diabetes, The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Jan 29, 2019 5:13:00 PM
prof-dr-freimut-schliess

Profil explores opportunities for artificial pancreas in type 2 diabetes

Highlighting the role of open and trans-sectoral collaboration in the advancement of artificial pancreas solutions

Profil has recently published a peer-reviewed article on the topic of “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project ” in the Journal of Diabetes Science and Technology. Profil is the organisation coordinating CLOSE. The article is authored by CLOSE industry and academic partners, representatives of the EIT Health public-private partnership management boards, and key opinion leaders in the field.

Read More

Topics: Treating Diabetes, Diabetes Technology, The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Oct 2, 2018 5:18:00 PM
prof-dr-freimut-schliess

Do-It-Yourself Artificial Pancreas systems (DIY APS)

The way forward to closed-loop metabolic control in diabetes care?

The challenge

Diabetes represents a huge and multidimensional challenge. Despite the availability of numerous treatment options, many patents still fail to reach their treatment goals. Administration of  the right amount of insulin at the right time still poses a great challenge for the self-management of many people with diabetes.

Accordingly there is a huge need to implement new innovative products and services improving both the effectiveness of diabetes care and the quality of life for people with diabetes. Particularly user-centered products and sercvices co-created with stakeholders including people with diabetes may have a high potential to increase treatment adherence thereby reducing the enormous pressure on healthcare systems.

Read More

Topics: Diabetes Technology, Treating Diabetes, The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Sep 5, 2018 5:16:00 PM
prof-dr-freimut-schliess

D4kids: Profil joined a new pan-European Artificial Pancreas initiative

Profil is part of the new Diabeloop for children (D4kids) pan-European consortium for functionally enhancing an Artificial Pancreas (AP) system to better serve the needs and requirements of children with type 1 diabetes (T1D) and their families.

Based on a co-creative approach and clinical evidence D4kids will adapt the AP system with the ambition to

  • ameliorate the long-term trajectories of T1D
  • enhance the quality of life of children and their families
  • boost pediatric care
  • improve the sustainability of European healthcare Systems
Read More

Topics: Treating Diabetes, About Profil

Posted by Prof. Dr. Freimut Schliess on May 2, 2018 4:53:00 PM
prof-dr-freimut-schliess

Artificial pancreas for type 2 diabetes: the CLOSE project

There is a great and ever increasing socioeconomic burden on Europe due to the prevalence of people with multiple chronic diseases. CLOSE (Automated glucose control at home for people with chronic disease) serves to innovate homecare for insulin treated patients with type 2 diabetes mellitus (T2DM) by offering an integrated product and service package (AP+). Blood glucose levels will be controlled by an artificial pancreas (AP) that will be installed at the patients' home, operated through trained caregivers, and remote controlled (telehealth).

Read More

Topics: Treating Diabetes, Clinical Trials in Diabetes

Posted by Prof. Dr. Freimut Schliess on Jan 18, 2018 5:03:00 PM
prof-dr-freimut-schliess

Glucose Clamps: 2 steps towards hepatic and peripheral insulin sensitivity

Context

The hyperinsulinemic euglycemic clamp is the gold standard required by regulatory authorities for quantifying the glucodynamics of insulin preparations in clinical trials. Glucose clamping avoids confounding effects due to fluctuations in blood glucose concentrations as seen in the insulin tolerance test.

The hyperinsulinemic euglycemic clamp is also the method of choice for measuring human insulin sensitivity in clinical trials (deFronzo et al., 1979; Heise & Heinemann, 2001; Heise et al., 2016). Today CE-labeled medical devices like ClampArt® are available. ClampArt® takes advantage from an intravenous (iv) continuous blood glucose monitoring and a smart algorithm.

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Aug 9, 2017 5:00:00 PM
prof-dr-freimut-schliess

InnoDiaCare: Summer School for Digital Innovation in Diabetes Care

Profil is proud to be part of the InnoDiaCare Summer School which is partnering with the CLOSE EIT Health innovation project on automated glucose control at home for patients with type 2 diabetes mellitus.

The InnoDiaCare Summer School for Digital innovation in Diabetes Care will be held in Poland (July) and in Germany (August). It is aimed at students and graduates to master their entrepreneurial skills and to empower them to create new business ideas on digital diabetes management.

Read More

Topics: Events

Posted by Prof. Dr. Freimut Schliess on May 5, 2017 5:00:00 PM
prof-dr-freimut-schliess

Glucose clamps: 2 steps towards insulin sensitivity adjusted for glucose effectiveness

Context

When adopting a glucocentric view on diabetes the hyperinsulinemic euglycemic clamp sets the gold standard for recording insulin sensitivity and time-action profiles in clinical trials (deFronzo et al., 1979; Heise & Heinemann, 2001; Heise et al., 2016). Both assessments capture the decrease of blood glucose levels following administration of exogenous insulin which again reflects the modulation of cellular glucose uptake and metabolism exerted by the hormone. Compensating for the insulin-induced decrease of blood glucose levels by clamping a defined blood glucose concentration helps to avoid effects related to fluctuating blood glucose concentrations and the physiological response to hypoglycemic states which would confound insulin sensitivity assessment. 

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Mar 16, 2017 4:53:00 PM
prof-dr-freimut-schliess

Liver first ? Part III: Medical Needs

In part II and part I of this series you read about the lessons learnt from preclinical work with respect to NASH and NAFLD. In this last part we will look at the medical needs, possible interventions and clinical trials in this area. Enjoy reading and don't forget to register for our monthly blog mailer (to the right of this page) so you won't miss future posts. 

Medical needs

Lifestyle interventions. Although lifestyle changes have been recognised to be a cornerstone in the prevention of diabetes, fatty liver, NASH and cardiovascular disease (Barb et al., 2016) sustainable regimes are difficult to implement and often hamper from a limited compliance of targeted people. There is a general gap between the broad availability of quality information on the impact of livestyle for health promotion and chronic disease prevention on the one hand, and the translation of into behavioural attitudes on the other.

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Dec 9, 2016 5:01:00 PM
prof-dr-freimut-schliess

Subscribe to our monthly blog updates

New Call-to-action

Subscribe to Email Updates

Our most popular Posts